FCCC LOGO Faculty Publications
Langer CJ , Wakelee H , Schiller J , Choy H , Shepherd F , Vokes EE , Adjei AA , Baas P , Saijo N , Gandara DR
Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?
Clin Lung Cancer. 2008 Mar;9(2) :85-91
PMID: 18501094   
Back to previous list
Abstract
Combined-modality therapy has emerged as the standard of care for fit patients with unresectable, locally advanced non-small-cell lung cancer (NSCLC). Concurrent chemotherapy/radiation has demonstrated therapeutic superiority compared with sequential or asynchronous chemotherapy and radiation in this setting. The role of consolidation or maintenance therapy with targeted agents or conventional cytotoxic agents remains unclear. We explore the portfolio of clinical trials being conducted in locally advanced NSCLC by North American cooperative oncology groups as well as ongoing trials in Europe and Japan. These efforts focus on radiation dose escalation using image-guided radiation therapy as well as newer cytotoxic agents (eg, pemetrexed) and targeted therapies (eg, cetuximab, bevacizumab, and etc) thus far unexplored in this setting.
Notes
Langer, Corey J Wakelee, Heather Schiller, Joan Choy, Hak Shepherd, Frances Vokes, Everett E Adjei, Alex A Baas, Paul Saijo, Nagahiro Gandara, David R Review United States Clinical lung cancer Clin Lung Cancer. 2008 Mar;9(2):85-91.